SANGAMO THERAPEUTICS, INC
No enriched coverage for $SGMO in the last 7 days.
No SEC Form 4 filings for $SGMO in the last 30 days.
See all $SGMO insider activity →Sangamo Therapeutics said it has signed two asset sale agreements—one with Eli Lilly for its capsid delivery platform and zinc finger platform, and another with Astellas. The company also began voluntary Chapter 11 proceedings, stating it plans to complete the sales through the reorganization to maximize value for stakeholders.
SANGAMO THERAPEUTICS, INC (SGMO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K SANGAMO THERAPEUTICS, INC NASDAQ false 0001001233 0001001233 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of ea
BRISBANE, Calif., Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of ...
Recent SGMO coverage spans financial news, mergers & acquisitions and corporate actions.
Chapter 11 plus platform asset sales is a material restructuring event that can reset equity recovery expectations and near-term funding risk.
The 8-K discloses a bankruptcy-era stalking-horse bid that can accelerate asset sale outcomes and materially change SGMO’s value path.
Minimal impact expected on Sangamo Therapeutics' stock from this news.
The FDA's acceptance of Sangamo's BLA rolling submission for ST-920 in Fabry disease is a positive development, potentially accelerating approval and commercialization.
Sangamo's Q3 2025 earnings call indicates steady progress in its gene therapy pipeline, with potential positive implications for its stock performance.
alphai scores every news story that mentions SGMO with an AI model for sentiment and relevance, and aggregates insider trades from SANGAMO THERAPEUTICS, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Sangamo Therapeutics said it has signed two asset sale agreements—one with Eli Lilly for its capsid delivery platform and zinc finger platform, and another with Astellas. The company also began voluntary Chapter 11 proceedings, stating it plans to complete the sales through the reorganization to maximize value for stakeholders.
2 min readSANGAMO THERAPEUTICS, INC (SGMO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K SANGAMO THERAPEUTICS, INC NASDAQ false 0001001233 0001001233 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of ea
4 min readBRISBANE, Calif., Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of ...
2 min readU.S. FDA has accepted Sangamo's request for a rolling submission and review of the BLA for ST-920 in Fabry disease ...
3 min readImage source: The Motley Fool.Thursday, November 6, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min readHeld meeting with U.S. Food and Drug Administration ( FDA ) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate ( eGFR ) slope as an endpoint to support accelerated approval pathway for isaralgagene civaparvovec in Fabry disease.
3 min readTotality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care
3 min readSANGAMO THERAPEUTICS PRESENTS DETAILED DATA FROM REGISTRATIONAL STAAR STUDY IN FABRY DISEASE AT INTERNATIONAL CONGRESS OF INBORN ERRORS OF METABOLISM ...
2 min readSangamo (SGMO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 min readSangamo (SGMO) delivered earnings and revenue surprises of -14.29% and -9.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min read
